Genesis Cancer and Blood Institute
Community-based oncology and hematology practice in Arkansas delivering medical oncology and hematology care, infusion and imaging services, specialty pharmacy support, clinical trial access, and coordinated patient services across a network of regional clinics.
Industries
Nr. of Employees
medium (51-250)
Genesis Cancer and Blood Institute
2910 Cypress Road, Arkadelphia, AR 71923
Products
Medical Oncology
Treatment of cancer using chemotherapy, biological agents, targeted therapies, immunotherapy, and oral chemotherapy.
Hematology
Diagnosis and treatment of blood disorders and hematologic malignancies, including rare blood cancers and autoimmune conditions.
Specialty Infusion Services
Administration of infusion therapies for chronic diseases like anemia, Crohn’s disease, multiple sclerosis, and rheumatoid arthritis.
Diagnostic Imaging
Use of advanced imaging technologies to obtain detailed views of internal organs, bones, soft tissues, and blood vessels.
Radioligand Therapy
Targeted delivery of radiation to cancer cells using radiopharmaceuticals to minimize exposure to healthy tissue.
Pathology Services
Local laboratory testing for routine and specialized diagnostic needs to support patient care.
Medical Oncology
Treatment of cancer using chemotherapy, biological agents, targeted therapies, immunotherapy, and oral chemotherapy.
Hematology
Diagnosis and treatment of blood disorders and hematologic malignancies, including rare blood cancers and autoimmune conditions.
Specialty Infusion Services
Administration of infusion therapies for chronic diseases like anemia, Crohn’s disease, multiple sclerosis, and rheumatoid arthritis.
Diagnostic Imaging
Use of advanced imaging technologies to obtain detailed views of internal organs, bones, soft tissues, and blood vessels.
Radioligand Therapy
Targeted delivery of radiation to cancer cells using radiopharmaceuticals to minimize exposure to healthy tissue.
Pathology Services
Local laboratory testing for routine and specialized diagnostic needs to support patient care.
Services
Systemic cancer treatment including chemotherapy, targeted therapies, immunotherapy and oral regimens.
Diagnosis and treatment of hematologic malignancies and blood disorders.
Administration and management of bispecific T‑cell engager immunotherapies.
Advanced imaging services for diagnostic evaluation and treatment planning.
Targeted radiopharmaceutical treatments for selected metastatic and neuroendocrine cancers.
Local pathology and laboratory testing to support diagnosis and treatment monitoring.
Systemic cancer treatment including chemotherapy, targeted therapies, immunotherapy and oral regimens.
Diagnosis and treatment of hematologic malignancies and blood disorders.
Administration and management of bispecific T‑cell engager immunotherapies.
Advanced imaging services for diagnostic evaluation and treatment planning.
Targeted radiopharmaceutical treatments for selected metastatic and neuroendocrine cancers.
Local pathology and laboratory testing to support diagnosis and treatment monitoring.
Expertise Areas
- Medical oncology
- Hematology
- Community oncology operations
- Radiopharmaceutical therapy (radioligand therapy)
Key Technologies
- Radiopharmaceutical (radioligand) therapy
- Bispecific T‑cell engager (bispecific antibody) therapies
- Immunotherapy
- Targeted systemic therapies
News & Updates
Announcement of new medical oncologist joining the physician team and expansion of clinical staff.
Announcement of a board‑certified oncologist and hematologist joining the practice.
Network-level news about expanded access to bispecific T‑cell engager immunotherapies across community clinics.
Summary of research abstracts by network physicians presented at the ASCO 2025 annual meeting, including an abstract authored by a Genesis physician.
Announcement that multiple community practices, including Genesis, are offering FDA‑approved radiopharmaceutical therapies for select cancers.
Announcement of new medical oncologist joining the physician team and expansion of clinical staff.
Announcement of a board‑certified oncologist and hematologist joining the practice.
Network-level news about expanded access to bispecific T‑cell engager immunotherapies across community clinics.
Summary of research abstracts by network physicians presented at the ASCO 2025 annual meeting, including an abstract authored by a Genesis physician.
Announcement that multiple community practices, including Genesis, are offering FDA‑approved radiopharmaceutical therapies for select cancers.